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Abstract: Background: Lymphatic filariasis (LF) is a major cause of lymphedema, affecting over
16 million people globally. A daily, hygiene-centered self-care protocol is recommended and effective
in reducing acute attacks caused by secondary infections. It may also reverse lymphedema status
in early stages, but less so as lymphedema advances. Lymphatic stimulating activities such as
self-massage and deep-breathing have proven beneficial for cancer-related lymphedema, but have
not been tested in LF-settings. Therefore, an enhanced self-care protocol was trialed among people
affected by moderate to severe LF-related lymphedema in northern Bangladesh. Methods: Cluster
randomization was used to allocate participants to either standard- or enhanced-self-care groups.
Lymphedema status was determined by lymphedema stage, mid-calf circumference, and mid-calf
tissue compressibility. Results: There were 71 patients in each group and at 24 weeks, both groups had
experienced significant improvement in lymphedema status and reduction in acute attacks. There was
a significant and clinically relevant between-group difference in mid-calf tissue compressibility with
the biggest change observed on legs affected by severe lymphedema in the enhanced self-care group
(∆ 21.5%, −0.68 (−0.91, −0.45), p < 0.001). Conclusion: This study offers the first evidence for including
lymphatic stimulating activities in recommended self-care for people affected by moderate and severe
LF-related lymphedema.
Keywords: lymphedema; lymphatic filariasis; self-care; tissue tonometry; lower extremity;
massage; breathing
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1. Introduction
Lymphedema is a symptom of lymphatic failure and manifests as chronic connective tissue
disease [1,2]. Fluid, cells, and proteins usually removed by lymphatic pumping accumulate in the
tissue spaces between the skin and underlying muscle, and over time chronic inflammatory processes
change the tissue composition and architecture [2]. Early fluid-rich stages are followed by fibrosis and
fatty deposits in the middle stages, and advanced stages are marked by hyperkeratosis, papillomatosis,
and other skin diseases [3]. Lymphatic filariasis (LF), a vector-borne disease endemic to 72 low and
middle income countries (LMICs) including Bangladesh, is a major cause of lymphedema worldwide [4].
The World Health Organization (WHO) Global Programme to Eliminate LF (GPELF) aims to
concurrently interrupt transmission using preventive chemotherapy via mass drug administration
(MDA), and deliver morbidity management and disability prevention (MMDP) services to people with
clinical manifestations [5]. The acute manifestations of LF are known as acute attacks, and involve
debilitating episodes of pain, fever, and skin breakdown [4]. Chronic diseases are primarily hydrocele
and lymphedema, and while hydrocele can be reversed with surgery in most cases [6], lymphedema
has no surgical or pharmaceutical cure and must be managed for life through home-based self-care [7].
After 15 years of programmatic activities, Bangladesh has completed MDA and morbidity mapping,
and estimates are that over 30,000 people are living with LF-related lymphedema, around 25% of
whom are affected by lymphedema at an advanced stage [8–10].
Approaches to lymphedema management in LMICs must be implemented at a sustainable
cost to the patient, family, and community. As acute attacks are the greatest cause of distress and
disability, the WHO guidelines are centered around a daily, or twice daily, hygiene-centered regime of
meticulous washing and drying of the affected body parts to reduce the risk of secondary infections.
Adherence to the hygiene regime has been shown to reduce the frequency and duration of acute
attacks [11,12]. However, two systematic reviews on lymphedema self-care found that while these
standard recommendations may reverse some clinical signs in early or mild stage lymphedema,
hygiene alone is less effective in reducing lymphedema status in more advanced disease [13,14].
Other than simple exercises and elevation, recommended activities do not address the underlying
lymphatic failure, and although lymphatic massage and compression therapies are recommended
for advanced lymphedema, the WHO aide-memoire for national program managers concedes that,
“The complete set of measures is more complex but usually cannot be implemented in resource-poor settings.“ [7].
Evidence-based self-care activities practiced by other populations, such as people who develop
lymphedema after treatment for cancer, have not been trialed among people affected by lower-limb
lymphedema in LMIC. While compression therapies are expensive and impractical in many LF-settings,
activities shown to support lymphatic function such as deep breathing and self-massage [13] require
few resources and should not increase the financial burden to the family or community. Drawing on
evidence from research on cancer-related lymphedema, an enhanced self-care protocol was developed
and a detailed description has been published [15].
Objective measurements of lymphedema status range from simple tape measures of limb
circumference to nuclear imaging. No single measure is accepted as a universal standard and a
variety of measures is generally required to determine lymphedema status [1]. Low-cost measures
such as stage of lymphedema and limb circumference are commonly used in resource-poor settings
to provide empirical evidence for the efficacy of lymphedema interventions, but in more advanced
lymphedema these gross changes in limb status take a long time to reverse [16]. To support national scale
up of effective MMDP programs in LMICs, affordable and field-friendly devices are needed to quantify
early and clinically relevant improvements in lymphedema status, and several methods are available
to detect the sub-clinical changes which precede overt improvements including ultrasonography,
bio-impedance spectroscopy, and tissue tonometry [17–19]. Tissue tonometry has been used to quantify
tissue compressibility or stiffness as a measure of change in lymphedema associated pathology since
1992 [20], and is frequently used in research on cancer-related lymphedema to measure changes in
fibrotic induration and hyperkeratosis [20–22]. More recently it has been used to detect subclinical
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lymphatic associated change among asymptomatic young people in LF endemic regions of Papua
New Guinea and Myanmar [19,20]. In the Myanmar cohort, a handheld tonometer, the Indurometer
(Flinders and SA Biomedical Engineering, Australia), was able to detect a significant increase in mid-calf
tissue compressibility among asymptomatic young people who were infected with LF, indicating that
free fluid had begun to accumulate in the connective tissue spaces, even though there was no clinical
sign of swelling. The Indurometer has demonstrated good intra-rater reliability in several populations
including people affected by lower-limb lymphedema in this study [21,23–25].
The WHO guidelines on lymphedema management are interpreted and implemented by LF
endemic countries according to national health policy, and in Bangladesh the national LF Elimination
Program within the Ministry of Health and Family Welfare (MOHFW) delivers lymphedema services
to registered patients via community clinics (CCs). Patients and their caregivers are taught the
core components of self-care including washing and drying the affected body parts twice per day,
attending to entry lesions and interdigital lesions, range of motion exercises, and limb elevation.
A kit-box containing soap, washcloths, and medicated creams is provided, and patients can access
further supplies such as medicated creams at the CC. To determine if an enhanced lymphedema
self-care protocol incorporating activities for lymphatic stimulation can improve lymphedema status
among people affected by moderate to severe lymphedema, a clinical trial which compared the
enhanced self-care protocol to the WHO recommended standard self-care protocol was conducted.
Objective measures of lymphedema status were collected including lymphedema stage, mid-calf
circumference, and mid-calf tissue compressibility. The trial was conducted in Bangladesh and Ethiopia,
which have contrasting environments and stages of GPELF activities, and the results on the Bangladesh
cohort are presented here.
2. Materials and Methods
2.1. Study Design, Research Personnel, and Recruitment
The prevalence of lymphedema is highest in the northern areas of Bangladesh [8], and Nilphamari
District was chosen as it was not due to receive routine MMDP training during the study period.
A random number generator was used to select 20 CCs from a list of all CCs in Nilphamari. Using cluster
randomization, each CC was then allocated to either the standard self-care (control), or enhanced
self-care (intervention) group and all participants at each CC were trained in the same self-care protocol.
Follow-up measures and questionnaires were administered at four, twelve, and 24 weeks. Figure 1 is a
map of all included CCs in the Nilphamari District by group.
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Figure 1. Map of all included community clinics in Nilphamari District, Bangladesh.
Two research teams were formed by personnel from the MOHFW National LF Elimination
Program and the Centre for Injury Prevention and Research, Bangladesh in Dhaka. Each research team
comprised a clinical officer, data collector, research assistant, self-care trainer, and team supervisor.
At each CC, up to ten adults (≥18 years of age) affected by lymphedema at stage 3 or more
according to Dreyer, et al. [26], and a designated adult caregiver, were invited to participate in the study.
Two community health workers (CHW) at each CC were enrolled to be trained in the allocated protocol
and to provide ongoing support. Each participant (patient, caregiver, and CHW) was provided with a
written information sheet to keep in local language (Bangla), and the information was also explained
by research staff in Bangla. Volunteers were pre-screened by the supervisor and trainer to ensure
they had lymphedema of at least stage 3 in one or both legs [26], and where this was inconclusive,
the patient was enrolled, and the clinical officer determined eligibility. Pre-screening also ensured that
all patients had an adult caregiver available and that patients were excluded from the study if they
had other known co-morbidities which may contribute to edema such as diabetes or congestive heart
failure. The maximum of ten patients in each study center avoided over-loading the CHWs, but all
volunteers who were not enrolled in the study were invited to participate in the lymphedema self-care
training sessions.
2.2. Outcomes Measures and Data Collection
Data collection methods have been published previously [11,13]. Primary outcome measures
were change in lymphedema status as determined by (1) lymphedema stage [26], (2) mid-calf limb
circumference, and (3) mid-calf tissue compressibility. Secondary outcome measures were (1) frequency
and (2) duration of acute attacks and (3) days of work lost due to lymphedema. To record adherence to
the self-care protocol, a daily journal was kept by patients. Both legs of each patient were assessed and
affected legs were classified as stage 1–7 according to clinical signs [26], and legs without any sign
of lymphedema were classified as stage 0. Circumference and tissue compressibility measures were
taken at the mid-point between the popliteal crease and the base of the heel of each leg with the patient
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lying prone. Circumference was measured with a retractable tape measure and the clinical officers
were provided with a laminated instruction sheet (Supplementary Figure S1). All data were collected
in the morning and not later than 2 pm to avoid variations in fluid accumulation that typically present
towards the end of the day.
Tissue compressibility was quantified using the Indurometer (BME-1563; Flinders and SA
Biomedical Engineering, Bedford Park, Australia) and the protocol was published in an intra-rater
reliability analysis on the study population [23]. Briefly, the Indurometer is a handheld, battery-operated
unit with a 1-centimeter (cm) diameter indenter projecting through a 7-cm diameter Perspex® reference
plate. The measure is taken with the indenter perpendicular to the measurement point and the reference
plate parallel to the skin. The operator presses the device evenly into the skin and while the reference
plate remains on the skin, the indenter progresses as far as is permitted by the underlying tissue.
Once a load of 200 gm has been applied, a digital readout displays the distance the indenter was able
to extend beyond the reference plate (millimeters). Lower scores indicate more tissue stiffness (less
compressibility) and a higher score indicates softer tissue (more compressibility). The Indurometer has
a self-calibrating procedure that was performed daily before the first measure and the clinical officers
were provided with a laminated instruction sheet (Supplementary Figure S2).
Questionnaires were used to collect socio-demographic information and patients were asked
about their medical status and lymphedema history. Data on acute attacks and days of work lost
were elicited by recall over the previous one and six months [27]. The clinical officer administered the
study questionnaires and collected the objective measures, and the data collector entered the answers
and scores to the Open Data Kit Collect (ODK Collect) [28] application loaded to an electronic tablet
(Samsung Galaxy Tab A 10.1). A paper journal for each 4-week period and a pencil were provided.
2.3. Intervention
The detailed protocol for both groups and a description of the material supplied to the patients
has been published previously [15], a summary of which can be found in Supplementary Table S1.
Patients, caregivers, and CHWs in both study groups were trained in the core components of standard
lymphedema self-care including education on the cause of lymphedema. Patients were given the
MOHFW National LF Elimination Program kit-box of materials, which was modified to include a
pair of nail clippers, and could access support and additional medication if needed from the CC
as per standard MOHFW policy and procedure. The intervention group was additionally trained
in enhanced self-care components including deep breathing, leg exercises performed in the supine
position, and lymphatic massage. A 500-mL bottle of coconut oil was provided as a medium to
perform the massage, but people were able to use any other lubricant, or no lubricant, according
to their preference. In addition, there were recommendations to walk at least 15 min twice per day,
drink at least 5 glasses of fresh water daily, and to eat fresh fruit and vegetables on at least 4 days every
week. A color-printed brochure with diagrams of the allocated self-care protocol was provided to each
patient (Supplementary Figure S3). Patients and caregivers were trained in journal keeping and at
each follow-up, patients were reminded of their self-care training and had their journals checked for
adherence to the allocated activities.
The study was conducted in accordance with the Declaration of Helsinki [29] and approved by
the Bangladesh Medical Research Committee and the Liverpool School of Tropical Medicine Research
Ethics Committee (approval no. 012-18), and registered on the ISRCTN Registry, trial number 16764792.
All subjects gave their informed consent for inclusion before they participated in the study. The study
sponsor and funders had no role in study design or protocol development and no input into publication
of study outcomes.
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2.4. Analysis
Patient biometric measures were collected at baseline including height and weight, and leg
dominance was determined by asking the question, “Which leg would you use to kick a ball?”.
Lymphedema stages 1 and 2 were considered mild, stages 3 and 4 moderate, and stages 5–7 severe [17].
The stage of the most severe leg at baseline was used for whole person variables such as number of
acute attacks, and the stage of each leg at baseline was included as a fixed effect for circumference and
Indurometer scores. Circumference scores were derived from a single measure on each leg and the
Indurometer score was the average of three successive measures. The Indurometer units were not
available at baseline and therefore measures of tissue compressibility at the 4-week follow-up were
considered as baseline for Indurometer data.
The frequency and duration of acute attacks, and the number of lost working days due to
lymphedema in the previous one month and six months, were analyzed using Poisson logistic mixed
effects models. Time point, group (intervention or control), and maximum stage (none, moderate,
or severe) at baseline were included in the model as fixed effects. Random effects were used for cluster
and patient. After adjusting for stage at baseline, leg dominance was not a significant factor in this
cohort, and Indurometer and circumference data were analyzed as right and left legs. In keeping
with previous studies on lymphedema, a change of either ≥10% or ≥2cm in circumference score
was considered clinically relevant and for Indurometer scores a change of ≥10% was used [30,31].
Adherence to the self-care protocol was assessed as performance of the allocated self-care regimen on
at least 5 days per week.
All analyses were performed using Stata 15.1 (StataCorp, College Station, TX, USA) and a p-value of
less than 0.05 was considered statistically significant. Descriptive statistics are presented as median with
interquartile range for continuous variables and as frequency with percentage for categorical variables.
Linear mixed effects models were used to analyze Indurometer and circumference measurements for
each leg using the identity number as a random effect to account for non-independence of the leg pairs
belonging to one individual. Time point and group (intervention or control) were included in the
model as a priori. Leg dominancy and stage (none, mild, moderate or severe) at baseline were tested
for inclusion in the model as fixed effects. All interactions were examined for inclusion. Random effects
were used for cluster, patient, and leg (right or left) for Indurometer and circumference.
3. Results
3.1. Participants
A total of 160 patients, 160 designated caregivers and 36 CHWs were enrolled. Eighteen patients
(and their corresponding caregivers) were excluded, mainly due to being assessed as not having at
least one leg affected by stage 3 lymphedema or higher (n = 14). Of the 142 patients who were included
in the study, 71 patients and their caregivers were allocated to the standard self-care (controls), and 71
to the enhanced self-care (intervention) group. Over 90% of patients attended the 4- and 12-week
follow-ups and there was 89% return for the final 24-week measures (control 86%, intervention 93%,
p > 0.05). A flow chart of all patients through the study can be seen in Figure 2.
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Figure 2. Flow chart of patients through the study.
There were no significant differences between groups at baseline for age, gender, stage of
lymphedema, or circumference scores. There were also no differences in the number of acute attacks
and working days lost due to lymphedema over either the previous one month, or six months (Table 1).
At baseline, data were available on 284 legs and most were affected by moderate lymphedema (stages
3 and 4, n = 114 legs), 54 legs were affected by severe diseas (stages 5–7), and 12 had no clinical sign
of lymphedema (stage 0). Four legs were ass ssed as mi d (contro = 1 l g, intervention = 3 legs) and
although these legs wer included in the analysis model, there were too few to report on the results
(Supplementary Table S2).
Table 1. Participant characteristics at baseline.
Standard Self-Care Enhanced Self-Care
(Controls) (Intervention) p =
Participants n = 71 n = 71
Age, median (IQR) 55 (48, 65) 52 (45, 60) 0.16
Gender = female 55 (77%) 52 (73%) 0.56
Marital status = married 50 (71%) 59 (82%) 0.17
Highest education = illiterate 35 (50%) 48 (67%) 0.22
Maximum stage of lymphedema 0.22
= moderate n (%) 43 (61%) 50 (70%)
= severe n (%) 18 (39%) 21 (30%)
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Table 1. Cont.
Standard Self-Care Enhanced Self-Care
(Controls) (Intervention) p =
Acute attacks—last 1 month Median (IQR) 1 (0, 1) 1 (0, 1) 0.86
Workdays lost—last 1 month Median (IQR) 3 (0, 6) 4 (0, 7) 0.48
Acute attacks—last 6 months Median (IQR) 3.5 (1.5, 6) 3 (2, 6) 0.74
Workdays lost—last 6 months Median (IQR) 18 (8, 30) 18 (7, 30) 0.96
Circumference—left leg (cm) Median (IQR)Mean (SD
29.2 (24.6, 33.8)
29.4 (5.91)
27.8 (24.2, 32.4)
28.6 (6.80)
0.48
0.41
Circumference—right leg (cm) Median (IQR)Mean (SD)
30.5 (25.8, 34.1)
29.9 (5.75)
27.9 (24.9, 32.4)
29.2 (5.77)
0.25
0.40
Indurometer score—left leg * Median (IQR)Mean (SD)
3.20 (2.71, 3.62)
3.17 (0.78)
3.45 (2.95, 4.02)
3.48 (0.82)
0.03
0.03
Indurometer score—right leg* Median (IQR)Mean (SD)
3.51 (3, 3.86)
3.44 (0.76)
3.53 (3.18, 3.94)
3.56 (0.64)
0.40
0.34
Moderate lymphedema = stages 3–4, severe = stage 5–7. IQR = inter-quartile range, SD = standard deviation, *
Indurometer measures at 4 weeks.
Adherence to the allocated self-care routine increased in both groups over the course of the study
(control = 63–89%, intervention = 71–90%) and there were no between-group differences. At baseline,
caregivers spent a cumulative median of 3 days per week supporting lymphedema care and this had
increased to 4 days by 24 weeks (both groups).
3.2. Primary Outcomes
Change in lymphedema status was determined by a combination of limb stage, mid-calf
circumference, and mid-calf tissue compressibility. The proportion of people affected by severe
lymphedema fell from 19% at baseline to 9% at 24 weeks, as did the number of individual legs affected
by severe lymphedema (control 22.5–14.8%, intervention 15.5–11.4%). The proportion of legs assessed
as having no lymphedema also reduced slightly (control 38.0–35.2%, intervention 40.8–37.9%) while
legs assessed as moderate increased (control 38.7–50.8%, intervention 41.5–49.2%). Over the study
period, 16.1% of legs had reverted to a lower stage (controls n = 20, intervention n = 21), 6.3% progressed
to a higher stage (controls n = 7, intervention n = 9), and three legs assessed as stage 0 at baseline
had progressed to stage 3. Of the four legs affected by mild lymphedema at baseline, three legs
progressed from stage 2 to 3, and the one leg at stage 1 had reverted to stage 0 at 24 weeks. None of
the within-group changes were significant, and there were no significant between-group differences
(Supplementary Table S2).
Mid-calf circumference measures at baseline ranged between 19.4 and 52.3 cm. Overall,
legs affected by severe lymphedema in both groups were larger at mid-calf than legs without
lymphedema by 12 (49.6%) and 11 cm (45.5%) on the left and right legs respectively (Supplementary
Table S3). There were significant reductions in circumference measures on legs affected by moderate
and severe lymphedema in both groups at the 4- and 12-week follow-ups, but none were clinically
relevant (neither ≥10% or ≥2 cm). The biggest reduction was observed at 4 weeks on legs affected by
moderate lymphedema (control −1.53 cm (4.8%, p < 0.001), intervention −1.21 cm (3.9%, p < 0.001),
and for severe cases the biggest reduction was observed at 12 weeks (control −1.17 cm (3.3%, p = 0.001),
intervention −1.16 cm (3.2%, p = 0.001) (≥ 2 cm, nor ≥ 10%). Legs that were unaffected by lymphedema
at baseline (stage 0) also had a slight reduction in circumference at 4 weeks (control −0.42 cm (1.7%,
p = 0.205), intervention −0.1 cm, (0.4%, p = 0.743), but at 24 weeks the mid-calf circumference was
significantly larger than at baseline in both groups (controls +1.24 cm (5.1%), intervention +1.46 cm
(6.0%), p < 0.001 for both). Change in circumference measures from baseline to 12 and 24 weeks can be
seen in Figure 3.
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Indurometer measures at the 4-week follow-up were considere as baseline data for mid-calf
tissue compressibility. Scores ranged between 1.37 and 5.70 wit legs affect d by severe lymphedema
returning significantly lower scores compared to legs without lymphedema (severe (3.13 ± 0.89), stage 0
(3.47± 0.70), p= 0.008). At baseline (4 weeks), there was a significant between-group difference in whole
cohort Indurometer scores (adjusted difference of −0.31 (95% CI −0.55, −0.07), p = 0.012), but when legs
were stratified by stage here were no between-group difference (p = 0.086) (Supplementary Table S4).
After accounting for the between-group differences at 4 weeks, there were significant
between-group differences at the 12- and 24-week follow-ups (p < 0.001 for each time point, p = 0.016
for overall interaction between group and time). There were clinically relevant within-group changes
(≥10%) in both roups with the larg st c ange obse ved on gs affected by s vere lymphedema in
the intervention group at 12 weeks (21.5%, −0.68 (−0.91, −0.45), p < 0.001). At 24 weeks, the direction
of the change had reversed and while neither group returned completely to baseline (4 weeks),
only the intervention group retained a clinically relevant change compared to baseline (moderate cases
11.3% −0.41 (−0.57, −0.24), p < 0.001, severe cases 11.4%, −0.36 (−0.59, −0.12), p = 0.003). Change in
Indurometer scores by stage and group at 12 and 24 weeks are shown in Figure 4.
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It should be noted that lymphedema stage as an indicator of skin pathologies and tissue
fibrosis, and limb circumference as an indicator of limb swelling, both have a linear relationship with
lymphedema progression [1,31]. However, since tissue compressibility is determined by multiple
tissue components, Indurometer scores may capture changes in skin pathologies, extracellular fluid
loads and connective tissue fibrosis, and the direction of change should be interpreted in association
with other available objective measures [1,30,31].
3.3. Secondary Outcomes
At 24 weeks, both groups reported significant within-group reductions in the frequency and
duration of acute attacks but there were no significant between-group differences. At baseline,
more than 95% of patients (n = 136) reported that they had experienced at least one acute attack due
to lymphedema and of these, more than 95% had experienced at least one episode in the six months
prior to study commencement (n = 133, range 1–24 acute attacks, mean 4.77 ± 4.76, median 3 (IQR 2,
6)). Each episode had lasted an average of 4.67 ± 3.22 days and twelve patients reported episodes
lasting 10 days or more (range 1–20 days, median 4 (IQR 3,5)). After 24 weeks, people affected by
severe lymphedema reported the biggest decrease in frequency (controls −4.37 episodes, 1.16 (0.58,
1.73), intervention -4.55 episodes, 1.69 (0.81, 2.57)), while people affected by moderate lymphedema
had experienced the best reduction in the duration of each episode (median -−4 days, (IQR −2, −5))
with no-one reporting episodes of 10-or-more-days duration (Figure 5).
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Patient reports on the frequency and duration of acute attacks over the previous one month
follow a similar pattern with more than 70% of patients reporting one or more acute attacks during
the previous one month at baseline (n = 101, range 1–7 episodes, mean 4.46 ± 4.15, median 1 (IQR
0, 1)) and an average duration of 5.08 ± 3.56 days (median 4 (3, 5)). At 24 weeks, less than 30% of
patients reported any acute episodes in the previous one month (n = 38, range 1–7, mean 0.53 ± 1.11,
median 1 (IQR 0, 1)) and the mean duration of each episode was 3.82 ± 1.43 days (median 3.5 days
(3, 4)). People affected by severe lymphedema reported the best reduction in frequency (controls −0.74
episodes, 0.44 (0.18, 0.70), i tervention 0.16, 0.85 (0.42, 1.28)) and moderate cases experienced the best
reduction in duration (controls, −3.57 days 0.90 (0.50, 1.31), intervention −1.79 days 1.20 (0.76, 1.63),
Supplementary Table S5.
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More than 90% of patients (n = 128) reported losing at least one day of work due to lymphedema
in the six months prior to study commencement, but at 24 weeks only 40% of patients reported
one-or-more workdays lost during the study period (p < 0.001). People affected by severe lymphedema
were both the most impacted at baseline and reported the biggest improvement, but there were no
significant between-group differences. People affected by severe lymphedema in the control group
reported a median of 25 (IQR 13, 37) working days lost due to lymphedema in the six months prior
to the study, but only 5 (3, 8) working days lost during the study period. In the intervention group,
the median reduction among severe cases was from 26 (IQR 12, 39) days at baseline to 4 (2, 7) days at
24 weeks (Supplementary Table S6). Patient reports on workdays lost in the previous one month also
fell at every follow-up in both groups (p < 0.001), Figure 6.
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of excess fluid was drained away, and at 12 weeks the significant between-group and within-group
differences in Indurometer scores were large enough to be clinically relevant, with the greatest change
recorded among severe cases performing the enhanced-care activities. While mid-calf circumference
had essentially returned to baseline in limbs affected by lymphedema, tissue compressibility did not,
indicating that other changes in tissue composition were occurring in addition to movement of free
fluid. Although the study period was not long enough to detect significant changes in gross clinical
signs, the overall improvement in stage at 24 weeks indicates that skin and tissue pathology had begun
to improve, and suggests that the significant between-group differences in tissue compressibility at
24 weeks were due to presence of subclinical changes in tissue structure. Since these pre-cursor changes
led to overtly detectable changes in lymphedema progression, the size and significance of the changes
detected by Indurometry were an indication of the different rate of change between the study groups.
In keeping with multiple other studies [13,14] we found meaningful improvements in the frequency
and duration of acute attacks which is no doubt due to the hygiene-centered activities included in both
protocols. In a comparison of plain and antibacterial soaps, Addis and colleagues [12] also reported
the best improvement in acute attacks among the most severe cases and this was not related to the type
of soap used, demonstrating that the hygiene-related nature of the protocol alone is enough to reduce
acute episodes [27]. In our study, legs affected by moderate lymphedema had the most improvement
at 4 and 12 weeks while severe cases tended to improve more slowly and consistently to 24 weeks.
This is in keeping with the findings of Kerketta et al. [32] who noted that the efficacy of the footcare
intervention varied with lymphedema grade. In that study, which compared standard self-care to
standard self-care plus either of two drug regimens over 12 months, circumference reduction in all
groups was greatest among legs at the earlier stages of lymphedema, while more advanced cases had
the best improvement in the frequency of acute attacks. Likewise, legs in our study which had been
assessed as stage 0 at baseline recorded the biggest fluctuations in limb circumference and were the
only limbs to have a significant increase at 24 weeks. These studies illustrate that the opportunity
to remove free fluid and reduce swelling declines as lymphedema stage advances, and support the
implementation of lymphedema self-care at the earliest possible stage.
People affected by severe lymphedema also suffer the most interruption in their ability to perform
work, and in our study there were significant improvements in the number of working days lost due
to lymphedema over the study period. This benefit may be amplified by the flow-on effect of freeing
up caregivers who also lose workdays due to caring for people affected by lymphedema, and whose
time is most frequently required during acute attacks [33,34]. As severe lymphedema improves more
slowly than earlier stages, studies of longer duration are needed to determine whether enhanced
self-care delivers better long-term benefits than standard self-care for these patients, but given the
enormous economic benefits that can be returned to communities once lymphedema is managed [35–37],
ascertaining the most effective self-care activities is worth investigating.
The risk of LF transmission in Bangladesh is very low [8], so new infections are unlikely to
account for any change in lymphedema status. Likewise, adherence to the allocated protocol was
high in both groups, and increased over the duration of the study, so non-performance of the self-care
activities was also not a factor in the apparent “rebound” in some measures between 12 and 24 weeks.
Nevertheless, the necessity for routine patient monitoring and support has been reported in several
studies, and regular health worker support, patient, and caregiver re-training, and replenishment
of supplies are needed to achieve long-term results [11,27,38,39]. The implementation guidelines
for LF MMDP programs include monthly follow-up of patients for 3 months with an annual review
thereafter [7]. Therefore, endemic countries should be supported to develop sustainable, long-term
strategies for delivery of this minimum requirement to even the most remote communities affected
by lymphedema.
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The main strength of this study was the use of the Indurometer, which has the ability to quantify
subtle changes in connective tissue composition, and its inclusion as a primary outcome measure
enabled a deeper insight into early treatment effects than could have been shown by limb circumference
or lymphedema stage alone. However, there are limitations in study design and data collection,
which should be considered when interpreting the results. Since connective tissue pathology in
severe lymphedema takes years to accumulate and is removed very slowly, the study period was
not long enough to determine if the intervention can achieve more overt improvements over current
recommendations. The mid-point of the calf was chosen as it is the optimal point for assessing
lower-limb tissue compressibility [24], and collecting the circumference measure at the same point
allowed for these measures to be interpreted together. However, a single circumference measure does
not provide much information about overall limb volume and the addition of another circumference
measure at the ankle, the most typical area for swelling to accumulate, or the addition of other measures
such as a portable 3D scanner to calculate limb volume may have provided a more robust measure of
how the self-care protocols affected overall leg swelling. Whole cohort Indurometer scores at 4 weeks
were significantly different between groups, but without pre-study data there is no way of knowing if
this was as a result of differences achieved through the intervention, or if the between-group scores
had already been different at baseline. Finally, although one of the criteria in choosing the enhanced
self-care activities was to avoid additional financial burden to the family or community, no economic
analysis was performed, and it is not known if the cost of materials or the cost of extra caregiver time
had any significant economic impact.
This is the first randomized trial to investigate the use of simple lymphatic-stimulating self-care
activities, proven to be effective for cancer-related lymphedema by people affected by LF-related
lymphedema. Although compression therapies have been shown to improve patient outcomes in LF
endemic settings [40,41], they are expensive, impractical in most resource-poor rural settings, and may
increase the risk of secondary infection [27]. Cost free, lymphatic stimulating activities such as deep
abdominal breathing and self-massage are effective in improving lymphedema status, [13,42–44],
but are rarely included in management of LF-related lymphedema [45,46]. Furthermore, the inability to
objectively and easily measure early improvement in lymphedema status, especially for more advanced
cases, has potentially led to underreporting on the effectiveness of lymphedema self-care programs.
This has ramifications for providing evidence-based guidelines to LF endemic countries programs,
and hampers efforts to increase private donor support for national MMDP program requirements.
The Indurometer is a reliable, non-invasive, and field-friendly device which can detect and
quantify covert changes in tissue composition before more overt changes can be seen. This, or other
portable devices capable of capturing early indicators of change in lymphedema status should be
included in implementation research on interventions for LF-related lymphedema.
5. Conclusions
Most LF-endemic countries must work within limited budgets to deliver national-scale services
to people affected by LF-related lymphedema, and therefore depend on expert guidance from WHO
regarding the most effective, evidence-based treatment protocols. The significant changes in tissue
composition detected by Indurometry in our study provide the first indication that inclusion of
lymphatic-stimulating activities in lymphedema self-care protocols may benefit people affected by
moderate to severe lymphedema. Factors associated with the loss of some benefit at 24 weeks, and the
effects of lymphatic stimulation on early stage lymphedema require further investigation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/8/2444/s1,
Figure S1: Circumference measure instruction sheet, Figure S2: The Indurometer, Figure S3: Intervention protocols,
Table S1: Summary of the self-care protocols, Table S2: Lymphoedema stage, Table S3: Mid-calf Circumference,
Table S4: Indurometer scores, Table S5: Acute attacks, Table S6: Working days lost to lymphoedema.
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